SION — Sionna Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Sionna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 41.4 | 50.3 | 70.6 | 89 |
| Operating Profit | -41.4 | -50.3 | -70.6 | -89 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -40.2 | -47.3 | -61.7 | -75.3 |
| Net Income After Taxes | -40.2 | -47.3 | -61.7 | -75.3 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -40.2 | -47.3 | -61.7 | -75.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -40.2 | -47.3 | -61.7 | -75.3 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.946 | -1.11 | -1.45 | -1.88 |